JP2008536487A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536487A5
JP2008536487A5 JP2008501411A JP2008501411A JP2008536487A5 JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5 JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5
Authority
JP
Japan
Prior art keywords
cells
activated
tumor cell
atcp
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008501411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536487A (ja
JP5663135B2 (ja
Filing date
Publication date
Priority claimed from GB0505508A external-priority patent/GB0505508D0/en
Priority claimed from GB0514288A external-priority patent/GB0514288D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000960 external-priority patent/WO2006097743A2/en
Publication of JP2008536487A publication Critical patent/JP2008536487A/ja
Publication of JP2008536487A5 publication Critical patent/JP2008536487A5/ja
Application granted granted Critical
Publication of JP5663135B2 publication Critical patent/JP5663135B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008501411A 2005-03-17 2006-03-16 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 Expired - Fee Related JP5663135B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0505508A GB0505508D0 (en) 2005-03-17 2005-03-17 Method
GB0505508.2 2005-03-17
GB0514288.0 2005-07-12
GB0514288A GB0514288D0 (en) 2005-07-12 2005-07-12 Method
PCT/GB2006/000960 WO2006097743A2 (en) 2005-03-17 2006-03-16 Method for actvating natural killer cells by tumor cell preparation in vitro

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012224042A Division JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Division JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法

Publications (3)

Publication Number Publication Date
JP2008536487A JP2008536487A (ja) 2008-09-11
JP2008536487A5 true JP2008536487A5 (enExample) 2009-03-12
JP5663135B2 JP5663135B2 (ja) 2015-02-04

Family

ID=36992099

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008501411A Expired - Fee Related JP5663135B2 (ja) 2005-03-17 2006-03-16 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2012224042A Expired - Lifetime JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Withdrawn JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012224042A Expired - Lifetime JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Withdrawn JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法

Country Status (9)

Country Link
US (3) US8257970B2 (enExample)
EP (2) EP1863905B1 (enExample)
JP (3) JP5663135B2 (enExample)
AU (1) AU2006224313B2 (enExample)
CA (1) CA2601197C (enExample)
DK (1) DK1863905T3 (enExample)
ES (1) ES2566335T3 (enExample)
PL (1) PL1863905T3 (enExample)
WO (1) WO2006097743A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
SG193832A1 (en) * 2008-05-29 2013-10-30 Transgene Sa Biomarker for selecting patients and related methods
EP2451942A1 (en) * 2009-07-10 2012-05-16 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
WO2013132256A1 (en) 2012-03-07 2013-09-12 Ucl Business Plc Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals
CN104321425B (zh) * 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
ES2808914T3 (es) * 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
US10758567B2 (en) 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
DK3349769T3 (da) * 2015-12-07 2021-03-08 Immune Ventures LLC In vivo priming af naturlige killerceller
EP3596201A4 (en) * 2017-03-15 2020-12-09 Immune Ventures, LLC IN VIVO PRIMING OF NATURAL KILLER CELLS
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
AU2019328575B2 (en) * 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
WO2020257639A1 (en) * 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
KR20250118299A (ko) * 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690927A1 (en) * 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell

Similar Documents

Publication Publication Date Title
Ginckels et al. Oxidative stress and inflammation in cardiovascular diseases and cancer: role of non-coding RNAs
Pancione et al. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis
Nehrbas et al. Extracellular vesicles and chemotherapy resistance in the AML microenvironment
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
Liu et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
Montoya et al. Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies
MX2010010726A (es) Composicion de estilizado de cabello.
Wang et al. Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool
BRPI0612612A2 (pt) compàsitos de celulose reconstituÍdos por lÍquido iânico como matrizes de suporte sàlido
JP2016501013A5 (enExample)
JP2009507918A5 (enExample)
JP2008519047A5 (enExample)
NZ599825A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
Li et al. ADAR1 attenuates allogeneic graft rejection by suppressing miR‐21 biogenesis in macrophages and promoting M2 polarization
Kanat et al. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer
JP2009232853A5 (enExample)
JP2009545620A5 (enExample)
Guo et al. Betaine effects on morphology, proliferation, and p53-induced apoptosis of hela cervical carcinoma cells in vitro
WO2017087947A3 (en) Method of treatment of follicular lymphoma with a btk inhibitor
Ziko et al. Mechanical Stress Promotes Cisplatin‐Induced Hepatocellular Carcinoma Cell Death
Huart et al. Could protons and carbon ions be the silver bullets against pancreatic cancer?
Kim et al. A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells
WO2017200492A1 (en) Method of treating cancer
WO2020060779A3 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle